Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children

Low-dose interleukin-2 (IL-2) therapy for chronic graft-versus-host disease (cGVHD) generates a rapid rise in plasma IL-2 levels and CD4(+)CD25(+)CD127(−)Foxp3(+) regulatory T-cell (CD4Treg) proliferation, but both decrease over time despite continued daily administration. To test whether IL-2 dose...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Whangbo, Jennifer S., Kim, Haesook T., Mirkovic, Nikola, Leonard, Lauren, Poryanda, Samuel, Silverstein, Sophie, Kim, Soomin, Reynolds, Carol G., Rai, Sharmila C., Verrill, Kelly, Lee, Michelle A., Margossian, Steven, Duncan, Christine, Lehmann, Leslie, Huang, Jennifer, Nikiforow, Sarah, Alyea, Edwin P., Armand, Philippe, Cutler, Corey S., Ho, Vincent T., Blazar, Bruce R., Antin, Joseph H., Soiffer, Robert J., Ritz, Jerome, Koreth, John
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2019
Assuntos:
Transplantation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6737411/
https://ncbi.nlm.nih.gov/pubmed/31471324
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000631
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados